Elanco Animal Health Business Summary

Elanco Animal Health Inc (ELAN) operates as a global leader in the animal health sector, generating revenue through the development, manufacture, and commercialization of a diverse portfolio of pharmaceuticals, vaccines, and nutritional additives. The company’s business is bifurcated into two primary segments: Pet Health, which provides parasiticides, vaccines, and therapeutics for companion animals, and Farm Animal, which focuses on protein production through medicated feed additives and health products for cattle, poultry, and swine. Revenue is primarily volume-driven, supported by a high-impact "Big 6" innovation pipeline—including blockbuster products like Credelio Quattro and Zenrelia—which is projected to contribute approximately $1.1 billion in revenue for 2026. Elanco maintains its position as the world’s third-largest animal health company, competing directly with industry giants such as Zoetis Inc., Merck Animal Health, and Phibro Animal Health Corporation by leveraging its extensive global distribution network and a strategic shift toward high-margin pet dermatology and sustainability-focused livestock solutions. Originally established as a division of Eli Lilly and Company in 1954, Elanco was spun off as a fully independent public entity in 2018 and significantly expanded its footprint through the 2020 acquisition of Bayer’s animal health business. The leadership team is headed by President and CEO Jeffrey N. Simmons, a veteran with over three decades of experience at the company who led its transition to independence. Key executives include Executive Vice President and CFO Robert VanHimbergen, who joined in 2025 to oversee the company's deleveraging strategy, and Dr. Ellen de Brabander, EVP of Innovation and Regulatory Affairs, who spearheads the R&D pipeline. The company’s digital and technological initiatives are managed by Rajeev (Bobby) Modi, EVP of Global Digital Transformation. The Board of Directors is chaired by Lawrence E. Kurzius, former CEO of McCormick & Company, and includes notable investor representation from Paul Herendeen, following a strategic cooperation agreement with activist investor Ancora Holdings Group LLC.